None
EN
The state of pharma’s chief marketing officers part 2: Being an ‘innovation catalyst’ for creativity
['.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar', 'Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright', 'Display Table .Wp-Block-Co-Authors-Plus-Avatar.Aligncenter Display Table Margin-Inline Auto']
News Archive - MM+M - Medical Marketing and Media
In the not too distant past, pharma lagged behind consumer advertising’s ability to churn out cutting-edge creativity.
Pharma chief marketing officers (CMOs) are increasingly tasked with incentivizing their marketing teams to produce a higher-quality level of creative that could compete with consumer brands — and meet patients where they are, beyond the doctor’s office.
At Lilly, the chief corporate brand officer is tasked with finding a strategic thread and unifying marketing functions under the overarching Lilly brand.
“There was the opportunity to create a system for marketing — we call it the ‘elements of marketing’ — and we talk about how marketing is a behavioral science.
Polimeni describes her own role as a protector of that creativity “safe space” in the workplace.
['space'
'role'
'creative'
'chief'
'pharma'
'creativity'
'cmo'
'cmos'
'officers'
'catalyst'
'marketing'
'corporate'
'pharmas'
'consumer'
'innovation'
'state']